Previous 10 | Next 10 |
The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics (ANGO) Presents At BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Slideshow
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the BTIG MedTech, Digital Hea...
Shares of medical instruments and supplies company AngioDynamics (NASDAQ: ANGO) have plunged nearly 25% in 2022, significantly underperforming the S&P 500 , which is also down 7% this year. Was the sell-off of AngioDynamics stock justified? More importantly, could i...
Margin shortfalls have been disappointing, but AngioDynamics' key growth drivers are still intact and the Med Tech portfolio is growing nicely. AngioVac remains the likeliest growth driver, though Auryon could surprise and NanoKnife could be a significant data-driven opportunity in a ...
Fiscal 2022 Second Quarter Highlights Net sales of $78.3 million increased 7.6% compared to the prior-year quarter Med Tech growth of 36.4% and Med Device growth of 0.8% year over year Gross margin of 51.8% declined 340 basis points year over year ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market ope...
The mantra of growth investing is to find and pay a fair price for quality stocks that are in the early stages of growth, with products or services that are gaining acceptance in the market. Operating in the medical devices industry with a market capitalization of $1.1 billion, AngioD...
Shares of a leading provider of minimally invasive medical devices, AngioDynamics (ANGO), have been surging on the back of solid revenue performance in its last reported quarter and continued investment in its Med Tech platform. However, given its uncertain growth outlook and the increasing c...
AngioDynamics, Inc. (ANGO) Q2 2022 Earnings Conference Call September 30, 2021, 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive Vice President and CFO Conference Call Participants Jayson Bedford - Raymond James Steven Lichtman - Oppenheimer & C...
The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: AngioDynamics, Inc. 2022 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...